In the U.S. “free market,” a vial of insulin that costs about $6 to manufacture is sold to patients and insurance companies for $275 a vial.

As a result, U.S. drug companies and middlemen have made massive profits on insulin, a drug used for diabetes since the 1920s. By 2017, the annual cost of diabetes to the U.S. economy was $327 billion in both health care and lost productivity.

After decades of pocketing a tidy profit on a drug that’s been around for 100 years, I hope Eli Lilly isn’t looking for a pat on the back for deciding to finally cap the price of insulin. No, indeed, it’s just wise enough to end the money-grab a step ahead of the growing recognition that this sort of corporate greed is costing the rest of us an extremely high price, and – in many cases – our lives.

Steve Kelley

Related Headlines

Only subscribers are eligible to post comments. Please subscribe or login first for digital access. Here’s why.

Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.

filed under: